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Abstract
Background: Few valid, disease-specific measures of health-related quality of life (HRQOL) capture the spectrum of symptoms associated with Huntington’s
disease (HD). The HD-PRO-TRIADTM is a new, HD-specific, patient-reported outcome (PRO) instrument of the HD symptom triad (cognitive decline,
emotional/behavioral dyscontrol, and motor dysfunction) designed for clinical research and practice. The objective was to validate the HD-PRO-TRIADTM
through a cross-sectional sample of individuals with HD and caregivers.
Methods: Development of the HD-PRO-TRIADTM has been described elsewhere. A total of 132 individuals with HD and 40 HD caregivers, comprising 29
dyads, participated in the cross-sectional psychometric validation of this instrument. Participants provided responses to the HD-PRO-TRIADTM and other
HRQOL and disease severity instruments (EuroQOL 5D, Short Form 12, Neuro-QOL Item Banks, PROMIS Global Health, and self-reported Unified
Huntington’s Disease Rating Scale Total Functional Capacity and Independence Scales). Internal consistency, construct validity, and patient–caregiver proxy
consistency were evaluated.
Results: Internal consistency of the three domains and overall HD-PRO-TRIADTM instrument was supported by Cronbach’s alpha values $0.94. Construct
validity was supported by significant correlations between HD-PRO-TRIADTM domain scores and other measures of the same domains (e.g., significant positive
correlations between HD-PRO-TRIADTM Anxiety with Neuro-QOL Anxiety), as well as slightly weaker but still strong correlations with other HRQOL
instruments (e.g., HD-PRO-TRIADTM Anxiety and UHDRS Independence; all p,0.01). Consistency between patient self-report and caregiver proxy report was
supported by an intra-class correlation coefficient $0.92 for all three domains and the overall instrument.
Discussion: These data indicate that HD-PRO-TRIADTM is a reliable and valid HRQOL instrument that captures the typical triad of HD symptoms.
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Introduction
Huntington’s disease (HD) is an autosomal-dominant neurodegen-
erative disease caused by a CAG trinucleotide repeat expansion in the
huntingtin gene on the short side of chromosome 4. HD is an insidious,
progressive disorder that causes deficits in the symptom triad of
cognitive, behavioral, and motor functioning.1,2 Symptoms gradually
appear and worsen over time, leading to a clinical diagnosis of HD
(currently based on unequivocal motor symptoms) often when affected
individuals reach their mid-40s. Death occurs approximately 20 years
after clinical diagnosis.1 Coping with the progressive symptoms of the
disease obviously affects an individual’s health-related quality of life
(HRQOL), a multidimensional construct used to determine the
impacts of HD and its symptoms on emotional, cognitive, social,
and physical well-being.3
Several qualitative studies4–7 have examined HRQOL in indivi-
duals with HD by employing either semi-structured interviews or focus
groups. Three semi-structured interview studies identified that
concerns with physical, emotional, cognitive, social, and day-to-day
functioning (including driving ability, interactions with others, house-
hold chores, conversing on the telephone, shopping, managing
finances, ability to work, and cooking) had a significant impact on
HRQOL.4–6 Similarly, a focus group study provided support for five
general HRQOL themes: emotional health (anxiety/fear, stigma,
anger, psychiatric/behavioral changes, positive psychological function,
resilience, and depression); social participation (interpersonal relation-
ships, leisure, vocation, and independence/autonomy); physical/
mental health (gene testing, involuntary movements/chorea, mobi-
lity/ambulation, speech and swallowing difficulties, medications,
health promotion, upper extremities, and weight loss); cognitive health
(learning/memory, executive function, and communication/compre-
hension); and end-of-life issues (planning, interactions with others with
HD, forward comparison).7 Collectively, these studies highlight the
multifaceted areas of HRQOL affected in individuals with HD.
Many quantitative studies have also examined generic (not HD-
specific) measures of HRQOL in HD, most using a single instru-
ment.5,8–16 However, generic HRQOL instruments do not fully cap-
ture the triad of symptoms characteristic of HD, nor are they sensitive
to change over time, which requires a more sensitive HRQOL assess-
ment in this population.
To address these shortcomings, two instruments have been recently
developed that target HD-specific HRQOL issues, the Huntington
Quality of Life Instrument (H-QoL-I)17 and the Huntington’s Disease
Health-Related Quality of Life questionnaire (HDQoL).17,18 The
H-QoL-I17 is an 11-item self-report instrument examining three
HRQOL dimensions: Motor Functioning, Psychology, and
Socializing. The HDQoL18 is a 40-item self-report instrument designed
to evaluate six subdomains: Cognitive, Hopes and Worries, Services,
Physical and Functional, Mood State, and Self and Vitality. The initial
publication for the H-QoL-I indicates it has acceptable internal
consistency (Cronbach’s alpha.0.84), as well as satisfactory construct,
discriminant, and external validity.17 Similarly, the initial publication on
the HDQoL indicates high reliability, stability, and internal consistency,
good unidimensionality, and good construct validity.18 However, these
findings have not been replicated in independent samples, and neither
instrument has been examined over time. The H-QoL-I is also limited
by its narrow scope, as it only evaluates two of the three symptom
domains characteristic of HD (motor and behavioral/emotional).
Although the HDQoL covers a wide range of HRQOL items, none
are chorea-specific. The HDQoL also takes approximately 20 minutes
to complete, which is acceptable in a research context, but might be
difficult to administer in a clinical setting.
The purpose of the current study was to develop and validate a new
instrument of HRQOL that 1) is specific to HD, 2) assesses fully the
triad of symptoms characteristic of HD, and 3) can be administered in
a clinical or research setting.
Methods
The development of the framework and content for the new HD-
specific HRQOL instrument (HD-PRO-TRIADTM) has been fully
described elsewhere.4 First, a literature review was conducted to
identify the triad of symptoms relevant to an HD-specific HRQOL
instrument. Individual phone-based interviews with individuals with
HD and caregivers, as well as an expert survey, were then conducted
to identify HRQOL issues important to individuals with HD and
develop items for a preliminary version of HD-PRO-TRIADTM. To
capitalize on advances from recent federally funded measurement
science efforts, we received permission to examine and include relevant
item content from Neuro-QOL,19 Traumatic Brain Injury-QOL,20,21
HDQLIFETM,7 and the Functional Assessment of Chronic Illness
Therapy (FACIT)22 measurement systems. Specifically, we considered
items from Neuro-QOL’s Cognition and Emotional and Behavioral
Dyscontrol item banks,23 and from Traumatic Brain Injury-QOL.20,21
Motor-related items were considered from the HDQLIFE item banks7
and from the FACIT22 system. After selecting and content matching
available items with patient, caregiver, and provider perspectives, we
drafted a preliminary instrument that was then cognitively tested in 10
individuals with HD.4 The resulting HD-PRO-TRIADTM (Version 1),
consisting of 47 items, was administered to 172 participants (132
individuals with HD and 40 caregivers) for psychometric testing. These
data were used to determine internal consistency, construct validity with
existing HRQOL measures, and determine consistency between
individuals with HD and their caregivers of HD-PRO-TRIADTM.
This process is summarized in Figure 1.
Individual phone-based interviews with HD patients and
caregivers
We conducted individual, semi-structured phone-based interviews
with 15 individuals with HD and 16 HD caregivers. Six pairs of
participants were patient–caregiver dyads. Audio recordings and notes
were taken during individual interviews, which were transcribed and
analyzed via NVivo 9.0 (QSR International Pty Ltd, Doncaster,
Australia), a qualitative data analysis and management software
package. Detailed results from the phone-based interviews are
published in Victorson et al.4 Content of the individual phone-based
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interviews was synthesized into a hierarchical domain framework,
which was used to identify HD-specific HRQOL themes and
dimensions. Items were developed to reflect three domains of
HRQOL: cognition, emotional/behavioral, and motor functioning.
This triad provided the basis for the item selection process.
HD-PRO-TRIADTM content selection process
Cognitive functioning items. The phone-based interviews indicated that
both individuals with HD and their caregivers expressed concerns with
cognition, including difficulties with executive functioning, memory, and
attention concentration. These concepts are captured by the Neuro-
QOL Cognition item banks24 and the TBI-QOL Cognition items.20,21
Therefore, 31 Neuro-QOL Cognition items (13 Executive Function and
18 General Concerns) and 32 TBI-QOL items were included for
consideration in the development of this measure.
Emotional/behavioral functioning items. The phone-based interviews
also highlighted concerns with emotional/behavioral functioning
including anger, depression, anxiety, and disinhibition, as well as
concepts captured by the Emotional and Behavioral Dyscontrol item
bank from the Neuro-QOL.24 Therefore, all 18 Neuro-QOL
Emotional and Behavioral Dyscontrol items were included for
consideration in development of this domain.
Motor functioning items. Furthermore, interview data highlighted
concerns with motor functioning, especially with regard to chorea. To
this end, we maintained the linkage to an HD-specific extension of
the Neuro-QOL system on motor functioning, which is also currently
under development.25 As such, we determined that the HDQLIFE
chorea items would be considered for inclusion in this measure, in
addition to other motor items from FACIT.22
Reading level and translations reviews. All items for the Neuro-QOL,
TBI-QOL, and HDQLIFE were written at or below a fifth-grade level
through the Lexile FrameworkTM.26 In addition, all Neuro-QOL,
TBI-QOL, and HDQLIFE items have undergone translatability
review to facilitate future translation of the final items into other
languages, particularly Spanish. New items underwent forward and
backward translation by two independent, native Spanish-speaking
translation science experts from different countries of origin.
Item review. All items were reviewed by experts in HD, including
physicians and nurse practitioners. Experts reviewed, revised, and
removed items as appropriate. Items were selected for deletion if they
were redundant, vague, or double-barreled, or if they were not
representative of the HD triad. The item pool was narrowed to 47
items (14 Cognition, 14 Emotional and Behavioral Dyscontrol, 19
Motor Function) during this process.
Each item in HD-PRO-TRIADTM was scored on a scale of 1–5,
with greater scores indicating worse functioning or HRQOL on each
domain. The total score for each domain was computed as a mean
based on the sum of scores of item responses divided by the number of
items answered. The possible maximum total score for each domain
was therefore 5 if the patient answered 5 to all items. The HD-PRO-
TRIADTM total score was computed as the sum of the three domain
total scores, with a possible maximum of 15.
HD-PRO-TRIADTM (version 1) psychometric validation
Participants. Participants were recruited through an online panel
testing company, OP4G (op4g.com), and through an exhibit/display
table at the 2012 annual meeting of the Huntington’s Disease Society
of America (HDSA). Inclusion criteria were prior diagnosis of HD (for
individuals with HD) or past or current role as a caregiver for someone
diagnosed with HD (for caregivers); age $18 at the time of study
participation; ability to actively participate in an online questionnaire;
and ability to read, write, speak, and understand English. Participants
completed the HD-PRO-TRIADTM instrument and the HRQOL and
disease severity tools described below. They accessed and completed
the self-reported instruments independently online via the Assessment
CenterSM (an online data capture system). The institutional review
board at Northwestern University approved this study.
Concurrent and divergent validation measures. The construct validity
of HD-PRO-TRIADTM was assessed against the following established
external HRQOL instruments (all completed by the patients and
caregivers).
EuroQOL 5D. The EuroQOL 5D (EQ-5D)27 is a five-item, standar-
dized, self-report instrument designed to evaluate general health status
(mobility, self-care, usual activities, pain/discomfort, anxiety/depres-
sion). It was scored from 0 to 1, with greater scores representing better
QOL.28
Short Form 12. The Short Form 12 (SF-12)29 is a 12-item self-report
instrument designed to evaluate HRQOL. Both the mental and
Figure 1. Development Framework and Process for HD-PRO-
TRIADTM. 1To identify the triad of symptoms relevant to an HD-specific
HRQOL instrument; 2To identify HRQOL issues important to individuals with
HD; 3Item development is an iterative process that includes the listed components.
HD, Huntington’s disease; HRQOL, Health-related quality of life.
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physical scales were assessed in this study. For each scale, the SF-12
was scored from 0 to 100, with greater scores indicating better QOL.
Neuro-QOL Item Banks. Neuro-QOL19 is a patient-related outcome
(PRO) measurement system designed to evaluate HRQOL in
individuals with neurologic diseases. Five-item banks were adminis-
tered from the Neuro-QOL: Anxiety, Depression, Ability to
Participate in Social Roles, Lower Extremity Function, and Upper
Extremity Function. Neuro-QOL item banks were administered as
static short forms. All Neuro-QOL scales were scored such that a
greater score represented more of the domain being measured. That is,
greater scores for Anxiety and Depression represented worse QOL,
while greater scores for Ability to Participate in Social Roles, Lower
Extremity Function, and Upper Extremity Function represented better
QOL. The T-score metric for all Neuro-QOL scales has a mean of 50
and standard deviation (SD) of 10.
PROMIS Global Health. Patient-Reported Outcomes Measurement
Information System (PROMISH)30,31 is a PRO measurement system
designed to evaluate HRQOL. The 10-item PROMIS Global Health
instrument yields two summary scores — Physical Health and Mental
Health. The PROMIS Global Health measures were scored according
to the PROMIS scoring algorithm. The T-score metric for all
PROMIS measures has a mean of 50 and SD of 10.
Self-reported functional capacity. The Unified Huntington’s Disease
Rating Scale (UHDRS) Total Functional Capacity (TFC) Scale,
designed as a clinician-administered and rated scale,31 was modified to
capture self-reported functional capacity (Appendix 1). This modified
self-report measure assessed functional capacity across five domains:
Occupation, Finances, Domestic Chores, Activities of Daily Living
(ADL), and Requirements for Unskilled or Skilled Care. Self-reported
functional capacity was computed as a sum of the scores for the five
domains (each ranging from 0 to 2 or 0 to 3), for a total score of 13,
with greater scores indicating better functioning.
Self-reported functional independence. We modified the UHDRS
Independence Scale (a clinician-rated scale) to be administered as a
self-report measure designed to evaluate functional independence
(Appendix 2).32 The scoring criteria for clinicians provided the anchors
for a 10-item scale assessing functional independence. Scores range from
1 to 10, with greater scores indicating lesser functional independence.
As referenced above, all items included in the HD-PRO-TRIAD
were existing items selected from either the Neuro-QOL/PROMIS,
TBI-QOL, or HDQLIFE measurement systems. Measures selected
from PROMIS/Neuro-QOL for validation purposes did not include
any overlap in items, as both measurement systems include multiple
assessments across several different domains of functioning.
Statistical analysis
HD-PRO-TRIADTM and validation instruments, as well as socio-
demographic and clinical characteristic questionnaires, were presented
to participants online through Assessment CenterSM. Descriptive
statistics were provided on socio-demographic and clinical character-
istics for both the patient and caregiver cohorts. Descriptive statistics
were calculated for HD-PRO-TRIADTM and the validation instru-
ments. Internal consistency of HD-PRO-TRIADTM was evaluated
using Cronbach’s coefficient alpha, item-total correlations, and inter-
item correlations. Construct validity (including convergent and
divergent validity) was examined using Pearson correlation coefficients.
We hypothesized that correlations between indices for similar
constructs would be high (.0.70). That is, we expected that the
HD-PRO-TRIADTM Emotional/Behavioral Dysfunction and other
measures of emotion such as Neuro-QOL Anxiety and Depression,
PROMIS Global Mental Health, and SF-12 Mental Component
would be highly correlated. Similarly, we anticipated we would
observe high correlations between HD-PRO-TRIADTM Motor
Function and Neuro-QOL Lower Extremity Function and Upper
Extremity Function, PROMIS Global Physical Health, and SF-12
Physical Component. We also anticipated HD-PRO-TRIADTM
Cognition would be highly correlated with measures of mental
health, physical health, and social health (i.e., Neuro-QOL Ability to
Participate in Social Roles). Intra-class correlation coefficients (ICCs)
were computed to assess the degree of consistency between HD patient
and caregiver proxy scores in the 29 HD patient–caregiver dyads.
Results
The resulting HD-PRO-TRIADTM (Version 1) is provided in
Appendix 3 (Figures 2 and 3). The Cognition and Emotional and
Behavioral Dyscontrol domains consist of 14 items, and the Motor
Function domain consists of 19 items. All items are rated 1 to 5. Each
domain is scored separately as an average score of all items responded
(1 to 5), and then added together for a total score. Total scores range
from 3 (least affected) to 15 (most affected).
Demographics and clinical characteristics
HD patients. A total of 132 individuals with HD and 40 HD caregivers
(spanning 29 HD patient–caregiver dyads) participated (Table 2). One
hundred and twenty-five of the HD individuals were recruited through
OP4G, and seven were recruited at the 2012 HDSA annual meeting.
Twenty-five caregivers were recruited through OP4G, and 15 were
recruited at the HDSA meeting. Demographics did not vary notably
between recruitment sources. Sixty-five percent of individuals with HD
reported a positive gene test, with an average self-reported CAG
repeat length of 44. Average self-reported time since HD diagnosis was 5
years, with individuals reporting the presence of motor symptoms for
an average of 6 years. Most individuals with HD reported that a parent
had HD (55% paternal and 23% maternal). Most individuals self-
reported their health statuses as good (37%), very good (19%), or
excellent (5%).
Caregivers. The 40 caregivers examined had an average age of 44
years and were primarily white and female (Table 1). Slightly more
than 50% of caregivers were caring for spouses or partners. The
remaining caregivers were caring for other family members (28%), HD
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Table 1. Demographic Characteristics of Individuals with HD and
Caregivers, and Clinical Characteristics of Individuals with HD as Reported







Age, mean (SD), years 40.8 (11.4) 43.9 (10.3)
Female, n (%) 63 (48%) 25 (63%)
Language, n (%)
English speaking 130 (98%) —
Spanish speaking 2 (2%) —
Hispanic, n (%) 14 (11%) 4 (10%)
Race, n (%)
Asian 7 (5%) 5 (13%)
Black 17 (13%) 6 (15%)
White 104 (79%) 27 (68%)
Other1 4 (3%) 2 (5%)
Education, n (%)
Less than high school 1 (1%) 0 (0%)
High school 22 (17%) 2 (5%)
Partial college 30 (23%) 10 (25%)
College 53 (40%) 11 (28%)
Graduate degree 26 (20%) 17 (43%)
Marital status, n (%)
Single 29 (22%) 3 (8%)
Married/Partnered 79 (60%) 35 (88%)
Divorced/Widowed 24 (18%) 2 (5%)
Family income, n (%)
,$5,000 2 (2%) 0 (0%)
$5,000 to $9,999 5 (4%) 0 (0%)
$10,000 to $19,999 8 (6%) 0 (0%)
$20,000 to $39,999 24 (18%) 5 (13%)
$40,000 to $74,999 41 (31%) 19 (48%)
$75,000 to $99,999 32 (24%) 7 (18%)






Unknown 2 (2%) 1 (3%)
Currently employed, n (%) 61 (46%) —
On disability, n (%) 62 (47%) —
Employed in same work
as before HD, n (% of
those currently
employed)
Yes 44/61 (72%) —
No 11/61 (18%) —
Not applicable/unknown 6/61 (10%) —
Clinical Characteristics




Gene testing, n (%) 86 (65%) 28 (70%)
CAG repeat length,
mean (SD)
43.6 (4.4) 43.9 (4.9)









5.0 (3.5) 5.7 (4.3)
Physician confirmed
showing of HD signs, n
(%)
106 (80%) —
Family HD history, n (%)
Father with HD 72 (55%) 20 (50%)
Mother with HD 31 (23%) 14 (35%)
Unknown 29 (22%) 6 (15%)
1Other races include American Indian, Hawaiian Pacific Islander, and
biraciality.
HD: Huntington’s disease; SD, standard deviation.
Dashes denote that the characteristics were not measured in
caregivers.
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HD-PRO-TRIADTM Cognition2 3.2 (1.1) 3.3 (1.2) 0.92 (0.84, 0.96)
Mental health
HD-PRO-TRIADTM Emotional/Behavioral 2.7 (1.0) 2.4 (0.9) 0.93 (0.86, 0.97)
Dyscontrol2
Neuro-QOL Anxiety3 57.5 (8.0) 54.9 (7.6) 0.87 (0.74, 0.94)
Neuro-QOL Depression3 54.1 (8.2) 51.6 (8.2) 0.86 (0.73, 0.93)
PROMIS Global Mental Health4 42.6 (9.7) 44.1 (9.7) 0.86 (0.73, 0.93)
SF-12 Mental Component5 41.3 (10.5) 43.6 (11.5) 0.83 (0.68, 0.91)
Physical Health
HD-PRO-TRIADTM Motor Function2 2.9 (1.0) 2.8 (1.1) 0.94 (0.88, 0.97)
Neuro-QOL Lower Extremity Function3 38.3 (10.9) 38.0 (11.2) 0.94 (0.88, 0.97)
Neuro-QOL Upper Extremity Function3 33.0 (11.6) 35.0 (14.3) 0.88 (0.77, 0.94)
PROMIS Global Physical Health4 39.0 (10.5) 41.1 (11.3) 0.90 (0.80, 0.95)
SF-12 Physical Component5 37.7 (10.8) 38.8 (12.5) 0.94 (0.88, 0.97)
Social Health
Neuro-QOL Ability to Participate in Social
Roles3
42.2 (7.4) 41.0 (8.8) 0.87 (0.75, 0.94)
Overall HRQOL
HD-PRO-TRIADTM Total2 8.8 (2.7) 8.5 (2.8) 0.95 (0.90, 0.98)
EQ-5D6 0.6 (0.3) 0.6 (0.3) 0.88 (0.77, 0.94)
Index of HD severity
UHDRS TFC7 6.8 (4.3) 5.4 (4.2) 0.96 (0.92, 0.98)
UHDRS Independence8 3.5 (2.3) 3.8 (2.2) 0.71 (0.48, 0.85)
1Intra-class correlation between HD individuals–self-reported (first column) and caregiver-reported (second column) scores.
2HD-PRO-TRIADTM Cognition, Emotional and Behavioral Dyscontrol, and Motor Function scores range from 1–5, with greater scores representing worse
functionality. HD-PRO-TRIADTM Total scores range from 3–15, with greater scores representing worse functionality.
3Neuro-QOL scores were converted to T-scores based on a T-score metric, with a mean of 50 and SD of 10. For Neuro-QOL Anxiety and Depression, a greater
T-score represents worse functionality, whereas in Neuro-QOL, Lower Extremity Function, Upper Extremity Function and Ability to Participate in Social Roles, a
greater T-score represents better functionality.
4PROMIS Global Mental Health and Physical Health scores were converted to T-scores based on a T-score metric, with a mean of 50 and SD of 10, with greater
T-scores representing better functionality.
5SF-12 Mental and Physical score range is 0–100, with greater scores representing better functionality.
6EQ-5D score range is 0–1, with greater scores representing better functionality.
7UHDRS TFC score range is 0–13, with greater scores representing better functionality.
8UHDRS Independence score range is 1–10, with greater scores representing worse functionality.
CI, confidence interval; ICC, intra-class correlation; SD, standard deviation.
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individuals in a nursing environment (13%), or friends (8%).
Caregivers had known their care recipients for an average of 19.8
years (SD of 13.1), and had been in the role of caregiver for an average
of 5.0 years (SD of 5.1).
Descriptive statistics
The mean HD-PRO-TRIADTM scores for individuals with HD
based on patient and caregiver reports were similar. Based on patient
reports, the mean scores for the three Cognition, Emotional and
Behavioral Dyscontrol, and Motor Function domains were 3.2 (range,
1.0–5.0; SD, 1.1), 2.7 (range, 1.0–5.0; SD, 1.0), and 2.9 (range, 1.0–
4.8; SD, 1.0), respectively. The total mean score for the overall
HD-PRO-TRIADTM instrument was 8.8 (Table 2). Descriptive
statistics for the other HRQOL instruments are also presented in
Table 2. Scores indicated that individuals with HD reported emotional
functioning at degrees comparable to the general population (e.g.,
Neuro-QOL and PROMIS emotional scores were within 1 SD of the
population mean of 50). However, degrees of physical functioning
were lower than that of the general population (as indicated by all but
one physical functioning score $1 SD below the mean).
Internal consistency
Internal consistency was excellent for all domains and the overall
HD-PRO-TRIADTM for both individuals with HD and caregivers (all
Cronbach’s alphas .0.95). In addition, item-total correlations ranged
from 0.54 to 0.90 for individuals with HD, and 0.43 to 0.94 for
caregivers. Likewise, inter-item correlations ranged from 0.14 to 0.88
for individuals with HD, and 20.14 to 0.90 for caregivers (Table 3).
Convergent and divergent validity
Strong evidence supports both convergent and divergent validity for
the three domains, as well as the overall HD-PRO-TRIADTM
instrument. In general, correlations were moderate to strong in the
HD patient sample (Table 4). The magnitudes of most correlation
coefficients for the relationships between HD-PRO-TRIADTM scores
and other HRQOL instruments were greater than 0.70. Moreover,
consistent with our hypotheses, correlations for HD-PRO-TRIADTM
Emotional/Behavioral Dysfunction were greatest with other measures
of emotion, while correlations between HD-PRO-TRIADTM Motor
Function and other indices of physical function were substantial. For
Cognition, correlations with other general HRQOL and disease
severity indices were moderate to strong.
Consistency between caregiver proxy and HD patient self-report
measures
Analysis of the data collected from the 29 HD patient–caregiver
dyads indicates substantial consistency between caregiver proxy and
HD patient self-reports. All intra-class correlations for the three
domains and the overall HD-PRO-TRIADTM instrument were
.0.90.
Table 3. Cronbach’s Alpha, Inter-Item, and Item-to-Total Correlations for HD-PRO-TRIADTM Domain and Total Scores from Individuals with HD and
Caregivers






Total 0.98 (0.14, 0.88) (0.54, 0.87)
Cognition 0.97 (0.60, 0.88) (0.78, 0.90)
Emotional/Behavioral Dyscontrol 0.96 (0.42, 0.87) (0.66, 0.86)
Motor Function 0.98 (0.40, 0.85) (0.64, 0.90)
Caregiver sample (N540)
HD-PRO-TRIADTM Domain
Total 0.98 (20.14, 0.90) (0.43, 0.90)
Cognition 0.98 (0.66, 0.89) (0.84, 0.92)
Emotional/Behavioral Dyscontrol 0.95 (0.24, 0.84) (0.63, 0.89)
Motor Function 0.98 (0.38, 0.90) (0.65, 0.94)
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Discussion
Understanding HRQOL in HD is a necessary component of
evaluating the effectiveness of clinical interventions. Furthermore, the
Food and Drug Administration requires a clinical outcome assessment
(COA) qualification for trials that demonstrate treatment benefit in
addition to clinical effectiveness. A COA qualification identifies drugs
with clear treatment benefits through both objective findings and
subjectively reported improvements. The lack of an HD-specific self-
report instrument with evidence of sensitive assessment over time has
made it difficult to evaluate the self-reported effectiveness of clinical
treatments. This study details the use, validity, and reliability of the
HD-PRO-TRIADTM, a new HD-specific instrument of HRQOL for
use in clinical research and in optimizing treatment in clinical practice.
This new instrument includes several items from pre-existing validated
measures (e.g., Neuro-QOL and HDQLIFE).
HD-PRO-TRIADTM is both reliable (internally consistent) and
valid, demonstrating convergent and divergent validity with other
HRQOL instruments. In particular, overall HD-PRO-TRIADTM
scores demonstrated strong relationships with all other HRQOL
instruments for both HD patient and caregiver proxy reports.
Similarly, the patterns among triad domains were as anticipated,
with the strongest relationships between corresponding measures
(e.g., correlations between HD-PRO-TRIADTM Emotional and
Behavioral Dysfunction were greatest with other measures of
emotion), and weaker relationships between each of the areas of the
triad.
Table 4. Pearson’s Correlations Between HD-PRO-TRIADTM and Other Instruments in Patient Sample (N5132)1
HD-PRO-TRIADTM
Total Cognition Emotional/Behavioral Dyscontrol Motor Function
Metric
Mental Health
Neuro-QOL Anxiety 0.70 0.62 0.75 0.51
Neuro-QOL Depression 0.71 0.61 0.75 0.54
PROMIS Global Mental Health2 0.77 0.72 0.73 0.62
SF-12 Mental Component2 0.61 0.61 0.53 0.51
Physical Health
Neuro-QOL Lower Extremity Function2 0.73 0.74 0.45 0.77
Neuro-QOL Upper Extremity Function2 0.74 0.73 0.44 0.81
PROMIS Global Physical Health2 0.82 0.83 0.57 0.80
SF-12 Physical Component2 0.76 0.77 0.47 0.79
Social Health
Neuro-QOL Ability to Participate in Social Roles2 0.55 0.61 0.27 0.58
Overall HRQOL
EQ-5D2 0.75 0.77 0.49 0.75
Index of HD severity
UHDRS TFC2 0.72 0.77 0.40 0.76
UHDRS Independence 0.59 0.58 0.35 0.66
All p,0.05.
1For HD-PRO-TRIADTM (Total, Cognition, Emotional and Behavioral Dyscontrol and Motor Function), Neuro-QOL (Anxiety and Depression), and UHDRS
Independence, greater scores represent worse functionality. For all other metrics (i.e., Neuro-QOL Lower Extremity Function, Upper Extremity Function, and Ability
to Participate in Social Roles, PROMIS Global Mental Health and Physical Health, EQ-5D, SF-12, and UHDRS TFC), greater scores represent better functionality.
2Correlations were negative between the two instruments assessed. In all cases, negative signs were expected because of differences in scoring methodology between
the two instruments. Negative signs were removed for consistent presentation purpose and to emphasize magnitude of correlations.
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There are often discrepancies between what individuals with HD
and their caregivers report to treating physicians. However, the HD-
PRO-TRIADTM proxy report and HD patient report were found to
be highly consistent, in sharp contrast with other HD research of
caregiver dyads that failed to find such a relationship.10 The
consistency between individuals with HD and their caregivers in our
study suggests that HD-PRO-TRIADTM may have utility in evaluat-
ing HRQOL for individuals with HD that may be unable to complete
these measures themselves.
The HD-PRO-TRIADTM includes 47 items (14 Cognition, 14
Emotional and Behavioral Dyscontrol, 19 Motor Function) and was
developed to be easily administered and scored in both clinical and
research settings. The intent of the authors is to have this instrument
publically available for use to clinicians and researchers via an online
domain. This measure is designed to capture PROs for individuals
with HD. However, there is much discussion in the HD community
about an individual’s ability to provide reliable self-report data during
the later phases of the disease, when both cognitive problems and
anosognosia are common.33–35 To this end, the general consensus is
that self-report measures, by themselves, only capture one component
of the clinical picture. Input from providers, caregivers, family
members, and patients themselves is needed to provide a full clinical
picture. Therefore, while PROs are an essential component of the
clinical picture, they should be used in conjunction with both clinician
and family-rated measures to build a complete clinical picture. Taken
together, the HD-PRO-TRIADTM captures the triad of symptoms
characteristic of HD.
While these findings highlight the initial reliability and validity of
HD-PRO-TRIADTM, future work in other HD patient samples is
needed to fully understand both the sensitivity and the strengths and
weaknesses of this instrument. Future work is needed to examine the
relationship of these items to objective assessments of emotional,
motor, and cognitive function and further refine this instrument by
selecting the most sensitive items, allowing quick administration of
HD-PRO-TRIADTM. In addition, the use of the instrument in the
context of an interventional trial still needs to be completed.
We acknowledge the limitations of this study. First, data were
collected via an online panel. Therefore, patient clinical characteristics,
including diagnoses, gene testing, years since diagnosis, and years with
symptoms, were self-reported and were not independently verified.
Indeed, this was a convenience sample rather than a clinical study
sample of HD patients. Second, we were only able to solicit self-
reported estimates of disease stage, functional ability, and indepen-
dence (rather than more typically used clinician-rated scales). Future
work is required to evaluate the relationship between the self-report
and clinician-rated versions of these scales. Third, while internal
consistency was excellent, as indicated by Cronbach’s alpha values
greater than 0.95, we note that excessively high internal consistency
may suggest item redundancy.36,37 That is, the items’ content may be
too narrow, with some not necessarily contributing incremental
additional information. While there are no standard cutoffs for
optimal internal consistency, it has been suggested that coefficient
alphas of at least 0.80 are considered sufficient, and limiting items to
no more than 35 for broad constructs (e.g., cognition, emotional/
behavioral dysfunction, and motor function) could reduce the risk of
redundancy.37 Nonetheless, item factor analysis should be explored in
future analyses to assess the need for further item reduction.
Both HD individuals and caregivers were instructed to take the
online instruments separately, on their own. During the recruitment of
participants at the HDSA meeting, HD individuals and caregivers
were also reminded orally that the survey needed to be filled out
separately and that HD individuals needed to be capable of filling out
the forms without assistance, as noted in the eligibility criteria.
However, we were not able to assess the extent to which such
instructions were followed, and that HD individuals and caregivers did
not share information. This is a fourth limitation of the study.
A final limitation is that the current study enrolled individuals with
HD who were able to independently complete online panel testing.
Therefore, application of the results may be limited to a greater-
functioning HD patient sample. Indeed, our patient sample was a very
well-educated group of fairly high-functioning individuals. This limits
the generalizability of our results at this time. In the future, this
instrument will also be evaluated for more moderate and more severe
individuals with HD who require 24-hour supervision. This instru-
ment, as with other HRQOL measures, is not appropriate for non-
verbal individuals. The validity of this instrument in individuals with
significant psychiatric issues, behavioral dyscontrol, or advanced
dementia will also need to be determined.
Since we found that the caregiver proxy measures are well-correlated
with the HD patient measures, the HD-PRO-TRIADTM instrument
may have the potential to be used for more severe individuals with HD.
Further prospective validation based on a larger patient sample over
multiple time points would confirm the dynamic validity of this
instrument. In addition, further validation of HD-PRO-TRIAD may be
achieved when consecutive individuals are recruited in the clinical
setting, with their HD histories recorded by neurologists through the
assistance of patients and caregivers; with full examinations undertaken
by neurologists; and with cognitive testing administered.
Despite these limitations, HD-PRO-TRIADTM provides an advan-
tage over more generic instruments of HRQOL that do not fully
capture the behavioral characteristics of this triad disorder. In
addition, the HD-PRO-TRIADTM does not have some of the
limitations of previous PRO measures developed for HD. The HD-
QOL-I17 is available in French and Italian, but not English. The HD-
QoL18 did not assess accepted norms for minimum sample patient
sizes for the analyses it employed.38 Moreover, the HD-PRO-
TRIADTM has demonstrated excellent reliability, as well as convergent
and divergent validity. The HD-PRO-TRIADTM is the first brief,
validated HRQOL instrument to assess the full triad of symptoms
associated with HD. Importantly, it is Neuro-QOL, HDQLIFE, and
PROMIS compatible. HD-PRO-TRIADTM should prove to be a
useful instrument for evaluating the effectiveness of clinical interven-
tions designed to improve the lives of individuals with HD.
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Appendix 1.
Unified Huntington’s Disease Rating Scale (UHDRS)
Modified Independence Scale
Please indicate the answer choice that best describes your current
independence level. Please choose only one response.
a) No special care is needed.
b) No physical care is needed if I avoid difficult tasks.
c) I have experienced changes in employment or have stopped
working. I am unable to perform household chores like I could
before my experience with Huntington’s Disease. I may need help
with finances.
d) I am able to bathe myself but I have limited household duties
(cooking and use of knives). I am unable to drive or manage
finances.
e) I require minor assistance in dressing, toileting, or bathing. Food
must be cut for me.
f) I require 24-hour supervision and assistance for bathing, eating,
and toileting.
g) I require services from a chronic care facility. I am limited in
feeding myself. I require a liquefied diet.
h) I provide minimal assistance in my own feeding, bathing, and
toileting.
i) I am unable to speak and must be fed.
j) I am tube fed and require total bed care.
Appendix 2.
Unified Huntington’s Disease Rating Scale_Total
Functional Capacity Scale, modified for assessment
center (caregiver version)
The following are questions on levels of functioning in the domains
of occupation, finances, domestic chores, activities of daily living, and
requirements for unskilled or skilled care. For each question, please
indicate the answer choice that best describes the ability of the person
with Huntington’s disease whom you care for (i.e., as the care receiver)
to accomplish the tasks described given his/her current Huntington’s
disease condition. In situations where the care receiver has not
performed a certain task to allow for your observation, please estimate
his/her ability to conduct such a task.
[UHDRS_occupation] Is the care receiver able to work?
05No, he/she is unable to work
15Yes, but he/she can only work part-time doing tasks that
are less complicated than his/her usual work
25Yes, but he/she needs special accommodations to get
his/her work done
35Yes, he/she can work normally with no accommodations
needed
[UHDRS_finances] Is the care receiver able to manage his/her own
finances?
05No, he/she is unable to manage his/her own finances
independently
15Yes, but with major assistance from another person/people
25Yes, but with slight assistance from another person/
people
35Yes, he/she can to manage finances independently
without assistance
HD-PRO-TRIADTM Validation Carlozzi NE, Victorson D, Sung V, et al.
Tremor and Other Hyperkinetic Movements
http://www.tremorjournal.org
The Center for Digital Research and Scholarship
Columbia University Libraries/Information Services11
[UHDRS_chores] Is the care receiver able to complete household
chores independently?
05No, he/she is unable to complete household chores
independently
15Yes, he/she can complete some, but not all, chores
independently
25Yes, he/she can complete all chores independently
[UHDRS_ADL] Is the care receiver able to accomplish daily living
tasks, such as bathing, dressing, and meal preparation independently?
05No, he/she is unable to accomplish daily living tasks
independently
15Yes, he/she can accomplish some, but not all, daily living
tasks independently
25Yes, he/she can accomplish many, but not all, daily
living tasks independently
35Yes, he/she can accomplish all daily living tasks
independently without assistance
[UHDRS_CareLevel] What type of care does the care receiver
receive?
05 he/she has full-time nursing care
15 he/she has part-time nursing help
25 he/she lives independently
Unified Huntington’s Disease Rating Scale_Total Functional
Capacity Scale, modified for assessment center
(patient version)
The following are questions on levels of functioning in the domains
of occupation, finances, domestic chores, activities of daily living, and
requirements for unskilled or skilled care. For each question, please
indicate the answer choice that best describes your ability to
accomplish the tasks described given your current Huntington’s
disease condition.
[UHDRS_occupation] Are you able to work?
05No, I am unable to work
15Yes, but I can only work part-time doing tasks that are
less complicated than my usual work
25Yes, but I need special accommodations to get my work
done
35Yes, I can work normally with no accommodations
needed
[UHDRS_finances] Are you able to manage your own finances?
05No, I am unable to manage my own finances
independently
15Yes, but with major assistance from another person/
people
25Yes, but with slight assistance from another person/people
35Yes, I can manage finances independently without
assistance
[UHDRS_chores] Are you able to complete household chores inde-
pendently?
05No, I am unable to complete household chores
independently
15Yes, I can complete some, but not all, chores indepen-
dently
25Yes, I can complete all chores independently
[UHDRS_ADL] Are you able to accomplish daily living tasks, such
as bathing, dressing, and meal preparation independently?
05No, I am unable to accomplish daily living tasks
independently
15Yes, I can accomplish some, but not all, daily living tasks
independently
25Yes, I can accomplish many, but not all, daily living tasks
independently
35Yes, I can accomplish all daily living tasks independently
without assistance
[UHDRS_CareLevel] What type of care do you receive?
05I have full-time nursing care
15I have part-time nursing help
25I live independently
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Appendix 3.
HD-PRO-TRIADTM Version 1
Figure 2. HD-PRO-TRIAD(tm) Domains (pages 1–5)
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Figure 2. Continued
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Figure 2. Continued
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Figure 2. Continued
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Figure 2. Continued
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Figure 3. HD-PRO-TRIADTM Instrument and Scoring Instructions (page 6–9)
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Figure 3. Continued
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Figure 3. Continued
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Figure 3. Continued
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